Wednesday, April 19, 2023 Daily Archives

Rapid Identification of Stable Biologic Candidates During Cell Line Development

by and

There’s no doubt that CHO cell lines are being pushed to their limits: Newer and more complex biologic modalities have low expression yield Dramatically higher concentration requirements of injectables Larger market demands with increasing awareness of new biologics based therapies. While advancements are being made, little has been done to characterize the physical stability of secreted antibodies from their inception during CHO cell line development. Scientists have been forced to stabilize biologics that were not designed with aggregation in mind…

April 19, 2023

J&J ups CAR-T capacity amid high Carvykti demand

by

Novartis to make Carvykti for Johnson & Johnson and its partner Legend Biotech to meet demand, says firm.  In March 2022, the US Food and Drug Administration (FDA) approved chimeric antigen receptor T-cell (CAR-T) therapy Carvykti (ciltacabtagene autoleucel; ciltacel). For the first three months of 2023, the multiple myeloma therapy pulled in $72 million in sales, up from $55 million quarter-on-quarter. J&J’s chief financial officer Joe Wolk said on the earnings call the firm is experiencing “really tremendous demand” for…

April 19, 2023

Danaher reportedly drops Catalent courtship, but is CDMO acquisition imminent?

by

Acquisition-hungry Danaher Corporation could continue to eye-up CDMO opportunities despite reports it has given up on Catalent. In February, the Danaher rumor mill turned to the tune of a potential $20+ billion takeover of contract development and manufacturing organization (CDMO) Catalent. But this week Bloomberg reported Danaher’s acquisitional interest has fallen, citing people familiar with the matter. Reasons why the alleged deal has fizzled out were not divulged, but Catalent’s stock price dropped 26% last week after the firm reported…

April 19, 2023

Eli Lilly invests a further $1.6bn at two Indiana plants

by

The $1.6 billion takes Eli Lilly’s spend to $3.7 billion and adds 200 jobs in Indiana. Eli Lilly and Company laid out $2.1 billion in May 2022 to construct two manufacturing facilities at LEAP Lebanon Innovation and Research District in Boone County, Indiana to expand its services for active ingredients and therapeutic modalities. Now, the firm has announced it will invest an additional $1.6 billion at the two plants. In turn, this will add another 200 new jobs at the manufacturing…

April 19, 2023

CHO business: Fujifilm Irvine bulks out media offering

by

Fujifilm Irvine Scientific has expanded its growth media business with products aimed at upping productivity of Chinese Hamster Ovary (CHO) cells in both perfusion and fed-batch bioprocesses. The latest expansion in Fujifilm Irvine Scientific’s cell culture media sees the firm add BalanCD CHO Perfusion and BalanCD CHO DG44, designed to maximize growth, viability, and productivity of Chinese Hamster Ovary (CHO) cell lines. “All media in the BalanCD CHO portfolio are chemically defined and optimized with the nutrients and components needed…

April 19, 2023